EP2780082A4 - COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE - Google Patents

COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE

Info

Publication number
EP2780082A4
EP2780082A4 EP12847618.1A EP12847618A EP2780082A4 EP 2780082 A4 EP2780082 A4 EP 2780082A4 EP 12847618 A EP12847618 A EP 12847618A EP 2780082 A4 EP2780082 A4 EP 2780082A4
Authority
EP
European Patent Office
Prior art keywords
disease
compositions
methods
treating alzheimer
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12847618.1A
Other languages
German (de)
French (fr)
Other versions
EP2780082A1 (en
Inventor
Neil R Cashman
Grant Mcclarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
CNJ Holdings Inc
Original Assignee
University of British Columbia
Cangene US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Cangene US Inc filed Critical University of British Columbia
Publication of EP2780082A1 publication Critical patent/EP2780082A1/en
Publication of EP2780082A4 publication Critical patent/EP2780082A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP12847618.1A 2011-11-10 2012-11-12 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Withdrawn EP2780082A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161558430P 2011-11-10 2011-11-10
US201261589809P 2012-01-23 2012-01-23
US201213582308A 2012-08-31 2012-08-31
PCT/US2012/064722 WO2013071267A1 (en) 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
EP2780082A1 EP2780082A1 (en) 2014-09-24
EP2780082A4 true EP2780082A4 (en) 2015-08-05

Family

ID=48290671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12847618.1A Withdrawn EP2780082A4 (en) 2011-11-10 2012-11-12 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE

Country Status (8)

Country Link
EP (1) EP2780082A4 (en)
CN (1) CN104093454A (en)
AU (1) AU2012335014A1 (en)
CA (1) CA2855669A1 (en)
EA (1) EA201491851A1 (en)
HK (1) HK1201771A1 (en)
SG (1) SG11201403272YA (en)
WO (1) WO2013071267A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6190113B2 (en) 2010-03-03 2017-08-30 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Oligomer-specific amyloid beta epitopes and antibodies
US20170008955A1 (en) * 2014-02-03 2017-01-12 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
AU2016264228B2 (en) * 2015-05-18 2019-06-13 Synaptec Development Llc Galantamine clearance of amyloidß
EP3374381A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia EPITAOPES IN THE CENTRAL REGION OF BETA-AMYLOID AND RELATED CONFORMATIONAL ANTIBODIES
KR102776187B1 (en) * 2015-11-09 2025-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 N-terminal epitope in amyloid beta and conformationally-selective antibodies thereto
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
CA3004493A1 (en) * 2015-11-09 2017-05-18 The University Of British Columiba C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3374382A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED SELECTIVE CONFORMATIONAL ANTIBODIES
CN109476729A (en) 2016-07-18 2019-03-15 英属哥伦比亚大学 Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10259865B2 (en) * 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN112661828B (en) * 2021-01-15 2022-04-01 武汉大学 An antigenic peptide of synaptophysin and its antibody and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002251A1 (en) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
WO2011106885A1 (en) * 2010-03-03 2011-09-09 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379504A2 (en) * 2008-12-22 2011-10-26 Sloan Kettering Institute For Cancer Research Coumarin-based compounds
JP2013518927A (en) * 2010-02-09 2013-05-23 ブリストル−マイヤーズ スクイブ カンパニー Measurement of clinical biomarkers using immunoassay standards and calibration standards in the assay

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002251A1 (en) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
WO2011106885A1 (en) * 2010-03-03 2011-09-09 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIAN O'NUALLAIN ET AL: "Human Plasma Contains Cross-Reactive A[beta] Conformer-Specific IgG Antibodies +", BIOCHEMISTRY, vol. 47, no. 47, 25 November 2008 (2008-11-25), pages 12254 - 12256, XP055198127, ISSN: 0006-2960, DOI: 10.1021/bi801767k *
MAGGA JOHANNA ET AL: "Human intravenous immunoglobulin provides protection against AÎ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease", JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, vol. 7, no. 1, 7 December 2010 (2010-12-07), pages 90, XP021089590, ISSN: 1742-2094, DOI: 10.1186/1742-2094-7-90 *
MICHELA ROSINI ET AL: "Inhibition of Acetylcholinesterase, [beta]-Amyloid Aggregation, and NMDA Receptors in Alzheimer's Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 15, 1 August 2008 (2008-08-01), pages 4381 - 4384, XP055198095, ISSN: 0022-2623, DOI: 10.1021/jm800577j *
See also references of WO2013071267A1 *

Also Published As

Publication number Publication date
EP2780082A1 (en) 2014-09-24
EA201491851A1 (en) 2015-12-30
HK1201771A1 (en) 2015-09-11
CN104093454A (en) 2014-10-08
CA2855669A1 (en) 2013-05-16
SG11201403272YA (en) 2014-08-28
AU2012335014A1 (en) 2014-06-19
WO2013071267A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
EP2780082A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
EP2819687A4 (en) COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE
EP2550263A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
EP2699256A4 (en) COMPOSITIONS AND METHODS FOR TREATING DEVIC DISEASE
EP2542255A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGOS DISEASE
EP2854852A4 (en) COMPOSITIONS AND METHODS FOR TREATING CROHN'S DISEASE AND ASSOCIATED PATHOLOGIES AND INFECTIONS
EP2707369A4 (en) Compositions and methods for treating alzheimer's disease
EP2892546A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN SCARING
EP2820159A4 (en) METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE
EP2608778A4 (en) COMPOSITIONS AND METHODS FOR TREATING BONE ANOMALIES
EP2854839A4 (en) METHODS OF TREATING C LIAQUE DISEASE
EP2766390A4 (en) COMPOSITIONS AND METHODS FOR TREATING CARDIAC INSUFFICIENCY
EP2635282A4 (en) COMPOSITIONS AND METHODS FOR TREATING MYELFIBROSIS
IL237369A0 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
EP2585075A4 (en) METHODS OF TREATING SOPHAGEAL INFLAMMATION
EP3019523A4 (en) METHODS OF TREATING ALZHEIMER'S DISEASE AND HUNTINGTON'S DISEASE
EP2795325A4 (en) DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE
EP2729148A4 (en) COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE
EP2723898A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF BLADDER CANCER
EP2863941A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF TYPE III LEFT DISEASE
EP2866894A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
EP2704723A4 (en) TREATMENT OF A POLYKYSTIC DISEASE
EP2786738A4 (en) HAIR TREATMENT AGENT COMPOSITION
EP2695154A4 (en) COMPUTER-AIDED ORTHOPHONY TREATMENT
PL2718434T3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOUS DISEASE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150703

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20150629BHEP

Ipc: C07K 16/06 20060101AFI20150629BHEP

Ipc: C07K 14/47 20060101ALI20150629BHEP

Ipc: A61K 39/395 20060101ALI20150629BHEP

Ipc: C07K 7/64 20060101ALI20150629BHEP

Ipc: A61P 25/28 20060101ALI20150629BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201771

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MCCLARTY, GRANT

Owner name: CANGENE U.S. INCORPORATED

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA

Owner name: CASHMAN, NEIL R.

Owner name: CANGENE CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CNJ HOLDINGS INC.

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA

17Q First examination report despatched

Effective date: 20170811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171222

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201771

Country of ref document: HK